Literature DB >> 24615265

Characterization of coxsackievirus B3 replication in human umbilical vein endothelial cells.

A Kühnl1, C Rien, K Spengler, N Kryeziu, A Sauerbrei, R Heller, A Henke.   

Abstract

After successful invasion of susceptible hosts, systemic distribution of coxsackievirus B3 (CVB3) most likely requires interactions with the endothelial system. Thereby, infection of endothelial cells occurs directly or viruses and/or virus-infected leukocytes migrate through the endothelial barrier. Many of these processes have not been studied so far. In order to analyze viral replication in the endothelium, human umbilical vein endothelial cells (HUVEC) were isolated and infected with CVB3. Time-course experiments revealed maximal viral replication at 10-24 h and viral RNA persistence up to 120 h post-infection (p. i.) without the induction of obvious general cytopathic effects or the loss of cellular viability. However, the application of the EGFP-expressing recombinant virus variant CVB3/EGFP revealed shrinkage and death of individual cells. Using infectious center assays, a noticeable CVB3 replication occurred on an average of 20 % of HUVEC at 10 h p. i. This may be in part due to a higher coxsackievirus/adenovirus receptor expression in a small subgroup of HUVEC (5-7 %) as analyzed by flow cytometry. Interestingly, CVB3 replication escalated and cellular susceptibility increased significantly after reversal of cell cycle arrest caused by serum deprivation indicating that reactivation of cellular metabolism may help to promote CVB3 replication. Finally, CVB3-infected HUVEC cultures revealed increased DNA fragmentation, and inhibition of caspase activity caused an accumulation of intracellular virus particles indicating that apoptotic processes are involved in virus release mechanisms. Based on these observations, it is assumed that CVB3 replicates efficiently in human endothelial cells. But how this specific infection of the endothelium may influence viral spread in the infected host needs to be investigated in the future.

Entities:  

Mesh:

Year:  2014        PMID: 24615265     DOI: 10.1007/s00430-014-0333-6

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  58 in total

1.  Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy.

Authors:  S A Huber; R C Budd; K Rossner; M K Newell
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

2.  L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin.

Authors:  R Heller; A Unbehaun; B Schellenberg; B Mayer; G Werner-Felmayer; E R Werner
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

3.  Impaired cardiac microvascular endothelial cells function induced by Coxsackievirus B3 infection and its potential role in cardiac fibrosis.

Authors:  Yeqing Xie; Jianquan Liao; Minghui Li; Xinggang Wang; Yingzhen Yang; Junbo Ge; Ruizhen Chen; Haozhu Chen
Journal:  Virus Res       Date:  2012-08-04       Impact factor: 3.303

4.  Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.

Authors:  Carsten Funke; Martin Farr; Bianca Werner; Sven Dittmann; Klaus Uberla; Cornelia Piper; Karsten Niehaus; Dieter Horstkotte
Journal:  J Gen Virol       Date:  2010-04-14       Impact factor: 3.891

5.  De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells.

Authors:  Michael Lagunoff; Jill Bechtel; Eleni Venetsanakos; Anne-Marie Roy; Nancy Abbey; Brian Herndier; Martin McMahon; Don Ganem
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy.

Authors:  H J Why; B T Meany; P J Richardson; E G Olsen; N E Bowles; L Cunningham; C A Freeke; L C Archard
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

7.  Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency.

Authors:  Ralph Feuer; Ignacio Mena; Robb R Pagarigan; Daniel E Hassett; J Lindsay Whitton
Journal:  Med Microbiol Immunol       Date:  2003-08-19       Impact factor: 3.402

8.  Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes.

Authors:  Nadine Jarasch; Ulrike Martin; Roland Zell; Peter Wutzler; Andreas Henke
Journal:  Apoptosis       Date:  2007-09       Impact factor: 4.677

9.  Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection.

Authors:  Christopher M Carthy; Bobby Yanagawa; Honglin Luo; David J Granville; Decheng Yang; Paul Cheung; Caroline Cheung; Mitra Esfandiarei; Charles M Rudin; Craig B Thompson; David W C Hunt; Bruce M McManus
Journal:  Virology       Date:  2003-08-15       Impact factor: 3.616

10.  Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.

Authors:  Ling Wang; Blossom Damania
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

View more
  1 in total

1.  The anti-obesity drug orlistat reveals anti-viral activity.

Authors:  Elisabeth Ammer; Sandor Nietzsche; Christian Rien; Alexander Kühnl; Theresa Mader; Regine Heller; Andreas Sauerbrei; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2015-02-14       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.